SCHEMBL5397969

SCHEMBL5397969

Cc1ccccc1CCN(CCC(=O)O)C(=O)c1ccccc1-c1ccccc1C(=O)NCc1ccc(F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C19 P33261 1/20 0.47
LMNA P02545 4/20 0.44
ALDH1A1 P00352 1/20 0.43
HTT P42858 4/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
MAPT P10636 1/20 0.43
HPGD P15428 2/20 0.42
CHRNB2 P17787 1/20 0.41
CHRNB4 P30926 1/20 0.41
CHRNA3 P32297 1/20 0.41
CHRNA4 P43681 1/20 0.41
MT-CO2 P00403 1/20 0.41
SLC6A5 Q9Y345 1/20 0.41
KCNA5 P22460 2/20 0.40
KCNK3 O14649 1/20 0.40
KCNK5 O95279 1/20 0.40
KCNK17 Q96T54 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5409890 0.93 CHRNB2 (0.48) KMT2ALMNAALDH1A1HTTSMN1; SMN2
SCHEMBL5401143 0.92 ALDH1A1 (0.53) KMT2ALMNAALDH1A1HTTSMN1; SMN2
SCHEMBL5398989 0.92 HTT (0.42) KMT2ACYP1A2CYP2C19LMNAALDH1A1
SCHEMBL4925864 0.91 ALDH1A1 (0.51) LMNAALDH1A1HTTL3MBTL1MAPT
SCHEMBL5403184 0.90 RAB9A (0.43) KMT2AALDH1A1HTTHPGDCHRNB2
SCHEMBL5394637 0.89 HPGD (0.54) KMT2ALMNAALDH1A1HTTSMN1; SMN2
SCHEMBL5418464 0.89 PLA2G1B (0.52) KMT2ACYP1A2CYP2C19LMNAALDH1A1
SCHEMBL5405937 0.89 ALDH1A1 (0.48) ALDH1A1MAPTHPGDSLC6A5KCNA5
SCHEMBL5402812 0.89 NR1H4 (0.47) LMNAALDH1A1HTTHPGDCHRNB2
SCHEMBL5408473 0.89 HTT (0.46) KMT2ALMNAALDH1A1HTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285680-B2 β-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-10-23 US disclosed
US-20050256160-A1 Beta-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2005-11-17 US disclosed
EP-1533294-A1 BETA-ALANINE DERIVATIVE AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256160-A1 Beta-alanine derivatives and the use thereof TGFB1, PML, APOB KMT2A 2451/4885CYP1A2 2649/4885CYP2C19 3960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.